{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:10:32Z","timestamp":1780499432062,"version":"3.54.1"},"reference-count":25,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2014,6,9]],"date-time":"2014-06-09T00:00:00Z","timestamp":1402272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Healthy Ageing Research Centre","award":["REGPOT-2012-2013-1, 7FP"],"award-info":[{"award-number":["REGPOT-2012-2013-1, 7FP"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>Desacyl ghrelin is a hormone that might be a functional inhibitor of ghrelin, a potent hunger\u2010stimulating peptide.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We determined fasting serum desacyl ghrelin levels in 24 subjects with schizophrenia on clozapine monotherapy and 24 healthy, age\u2010 and sex\u2010matched controls. Biochemical and anthropometric measurements were combined with body composition determined using bioelectric impedance analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were no differences in desacyl ghrelin levels between patients taking clozapine and the control group (272.09\u2009\u00b1\u2009137.96 vs 259.62\u2009\u00b1\u2009140.91\u2009pg\/mL, z\u2009=\u20090.17, <jats:italic>P<\/jats:italic>\u2009=\u20090.87). In the clozapine group, there were no differences between men and women for ghrelin levels (246.66\u2009\u00b1\u2009123.17 vs 295.39\u2009\u00b1\u2009151.77\u2009pg\/mL, z\u2009=\u2009\u22120.98, <jats:italic>P<\/jats:italic>\u2009=\u20090.32). In the clozapine group, fasting serum levels of ghrelin negatively correlated with waist\u2010to\u2010hip ratio (<jats:styled-content style=\"fixed-case\">WHR<\/jats:styled-content>) (r\u2009=\u2009\u22120.45, <jats:italic>P<\/jats:italic>\u2009=\u20090.03) and ionized calcium (r\u2009=\u2009\u22120.45, <jats:italic>P<\/jats:italic>\u2009=\u20090.03). Levels of ghrelin were lower in patients with <jats:styled-content style=\"fixed-case\">WHR<\/jats:styled-content> above World Health Organization\u2010defined cut\u2010off points (246.84\u2009\u00b1\u2009114.34 [Q1\u2009=\u2009152.18, Q2\u2009=\u2009220.92, Q3\u2009=\u2009327.85] vs 400.30\u2009\u00b1\u2009123.36 [Q1\u2009=\u2009283.73, Q2\u2009=\u2009414.03, Q3\u2009=\u2009485.8] pg\/mL, z\u2009=\u20092.52, <jats:italic>P<\/jats:italic>\u2009=\u20090.01). In the clozapine group, there were no correlation with age, height, weight, body mass index, abdominal circumference, waist circumference, hip circumference, <jats:styled-content style=\"fixed-case\">WHR<\/jats:styled-content>, blood pressure, total cholesterol, high\u2010density lipoproteins, low\u2010density lipoproteins, triglycerides, uric acid, homocysteine, glucose, insulin, clozapine dose, duration of treatment with antipsychotics, duration of treatment with clozapine, total fat, target fat, basal metabolic rate, target weight, lean weight, body water, homoeostasis model assessment of insulin resistance (<jats:styled-content style=\"fixed-case\">HOMA) 1<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content>, <jats:styled-content style=\"fixed-case\">HOMA2<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content> and quantitative insulin sensitivity check index.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Based on our results, we cannot conclude that treatment with clozapine affects levels of desacyl ghrelin. Also, in our study population we did not confirm previously described associations between desacyl ghrelin and various metabolic parameters.<\/jats:p><\/jats:sec>","DOI":"10.1111\/pcn.12199","type":"journal-article","created":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T02:54:50Z","timestamp":1398740090000},"page":"833-840","source":"Crossref","is-referenced-by-count":10,"title":["Serum levels of desacyl ghrelin in patients with schizophrenia on clozapine monotherapy"],"prefix":"10.1111","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6159-6579","authenticated-orcid":false,"given":"Adam","family":"Wysoki\u0144ski","sequence":"first","affiliation":[{"name":"Department of Old Age Psychiatry and Psychotic Disorders Medical University of Lodz  Lodz Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek L.","family":"Kowalski","sequence":"additional","affiliation":[{"name":"Department of Immunology, Rheumatology and Allergy Medical University of Lodz  Lodz Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"K\u0142oszewska","sequence":"additional","affiliation":[{"name":"Department of Old Age Psychiatry and Psychotic Disorders Medical University of Lodz  Lodz Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,6,9]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"e07","article-title":"Addressing nonresponse in schizophrenia","volume":"73","author":"Kane JM","year":"2012","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"e_1_2_6_3_1","first-page":"1","article-title":"Second\u2010generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review","volume":"19","author":"Newcomer JW","year":"2005","journal-title":"CNS Drugs"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200124010-00005"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1024\/1422-4917\/a000165"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300027"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-0089"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/45230"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M002784200"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2006-0006"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0456"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000176061"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2006.01858.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2007.01610.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2004.05.008"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2008.03.015"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2005.03.008"},{"key":"e_1_2_6_18_1","first-page":"132","article-title":"[Possible connection between ghrelin, resistin and TNF\u2010alpha levels and the metabolic syndrome caused by atypical antipsychotics]","volume":"7","author":"Birkas Kovats D","year":"2005","journal-title":"Neuropsychopharmacol. Hung."},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1642-4"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbm141"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000327367"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.038737"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0334"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2527"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.22983"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007038"}],"container-title":["Psychiatry and Clinical Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpcn.12199","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpcn.12199","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pcn.12199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T15:56:19Z","timestamp":1696002979000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pcn.12199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,9]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1111\/pcn.12199"],"URL":"https:\/\/doi.org\/10.1111\/pcn.12199","archive":["Portico"],"relation":{},"ISSN":["1323-1316","1440-1819"],"issn-type":[{"value":"1323-1316","type":"print"},{"value":"1440-1819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,9]]}}}